Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials

Abstract

Ignyta/F Hoffmann-La Roche.

Keywords

Trk receptorMedicineInternal medicineOncologyPopulationClinical trialCancerPhases of clinical researchResponse Evaluation Criteria in Solid TumorsReceptorNeurotrophin

MeSH Terms

AgedAntineoplastic AgentsBenzamidesBiomarkersTumorClinical TrialsPhase I as TopicClinical TrialsPhase II as TopicFemaleGene FusionHumansIndazolesMaleMembrane GlycoproteinsMiddle AgedNeoplasm MetastasisNeoplasmsProtein Kinase InhibitorsReceptortrkAReceptortrkBReceptortrkCReceptorsNerve Growth FactorTime FactorsTreatment Outcome

Affiliated Institutions

Related Publications

Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer

Peter Schmid , Sylvia Adams , Hope S. Rugo +15 more

Atezolizumab plus nab-paclitaxel prolonged progression-free survival among patients with metastatic triple-negative breast cancer in both the intention-to-treat population and t...

2018 New England Journal of Medicine 4116 citations

Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC

Mark A. Socinski , Robert M. Jotte , Federico Cappuzzo +17 more

The addition of atezolizumab to bevacizumab plus chemotherapy significantly improved progression-free survival and overall survival among patients with metastatic nonsquamous NS...

2018 New England Journal of Medicine 3592 citations

Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma

Richard S. Finn , Shukui Qin , Masafumi Ikeda +18 more

In patients with unresectable hepatocellular carcinoma, atezolizumab combined with bevacizumab resulted in better overall and progression-free survival outcomes than sorafenib. ...

2020 New England Journal of Medicine 6464 citations

A systematic review of the clinical effectiveness of first-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer

Gerlinde Pilkington , Angela Boland , Tamara Brown +3 more

Our aim was to evaluate the clinical effectiveness of chemotherapy treatments currently licensed in Europe and recommended by the National Institute for Health and Care Excellen...

2015 Thorax 116 citations

Data Sets for the Reporting of Tumors of the Central Nervous System: Recommendations From The International Collaboration on Cancer Reporting

David N. Louis , Pieter Wesseling , Sebastian Brandner +14 more

Context.— Standards for pathology reporting of cancer are foundational to national and international benchmarking, epidemiology, and clinical trials, with international standard...

2019 Archives of Pathology & Laboratory Me... 23 citations

Publication Info

Year: 2019
Type: article
Volume: 21
Issue: 2
Pages: 271-282
Citations: 1625
Access: Closed

External Links

Download PDF (Free) View on DOI.org PubMed Semantic Scholar

Social Impact

Altmetric

Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

1625

OpenAlex

Influential

1404

CrossRef

Cite This

APA Style

                            
                                
                                    Robert C. Doebele, 
                                
                                    Alexander Drilon, 
                                
                                    Luis Paz‐Ares
                                
                                et al.
                            
                            (2019). 
                            Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials. 
                            The Lancet Oncology
                            , 21
                            (2)
                            , 271-282.
                            https://doi.org/10.1016/s1470-2045(19)30691-6
                        

Identifiers

DOI: 10.1016/s1470-2045(19)30691-6
PMID: 31838007
PMCID: PMC7461630

Data Quality

Data completeness: 90%